Lion Biotechnologies, Inc. (LBIO)

Oncology Corporate Profile

Stock Performance

7.6000
0.0000

HQ Location

21900 Burbank Blvd., Third Floor
Woodland Hills, CA 91367

Company Description

"Lion Biotechnologies, Inc. is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage 4 metastatic melanoma, and is based on a clinical CRADA with the National Cancer Institute."

Website: http://lbio.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
NCI/Lion Bio(TIL) tumor infiltrating lymphocytesMelanomaII
NCI/Lion Bio (+ vemurafenib)(TIL) tumor infiltrating lymphocytesMelanomaI

View additional information on product candidates here »

Source


http://lbio.com

Recent News Headlines

Lion Biotechnologies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update

3/7/2017 09:00 pm

[Marketwired] - Lion Biotechnologies, Inc. , a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today reported its fourth quarter and full-year 2016 financial ...

Lion Biotechnologies to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and Operating Results on Tuesday, March 7, 2017

2/28/2017 01:00 pm

[Marketwired] - Lion Biotechnologies, Inc. , a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that it will report its fourth quarter and ...

Lion Biotechnologies to Present at Upcoming Investor Conferences in March

2/27/2017 01:00 pm

[Marketwired] - Lion Biotechnologies, Inc. , a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, announced today that company management will present a corporate ...

Lion Biotechnologies Announces New Sponsored Research and Clinical Grant Agreements with H. Lee Moffitt Cancer Center and Research Institute

12/20/2016 09:05 pm

[at noodls] - SAN CARLOS, CA -- (Marketwired) -- 12/20/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, ...

Lion Biotechnologies Announces New Sponsored Research and Clinical Grant Agreements with H. Lee Moffitt Cancer Center and Research Institute

12/20/2016 09:00 pm

[Marketwired] - Lion Biotechnologies, Inc. , a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, announced today that it has entered into a new three-year ...

Blog Coverage Lion Biotechnologies Signs a New Manufacturing Services Agreement with WuXi AppTec for its Cell Therapy Products

11/29/2016 01:01 pm

[Accesswire] - Upcoming AWS Coverage on Ultragenyx Pharmaceutical Post-Earnings Results LONDON, UK / ACCESSWIRE / November 29, 2016 / Active Wall St. blog coverage looks at the headline from Lion Biotechnologies, Inc. ...

Lion Biotechnologies Announces New Manufacturing Services Agreement with WuXi AppTec

11/28/2016 01:00 pm

[Marketwired] - Lion Biotechnologies, Inc. , a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology , announced today that it has entered into a new three-year ...

Lion Biotechnologies to Present at the 28th Annual Piper Jaffray Healthcare Conference

11/23/2016 01:00 pm

[Marketwired] - Lion Biotechnologies, Inc. , a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology , today announced that its President and Chief Executive Officer, ...